Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE – Get Rating) Chairman Armando Anido sold 35,453 shares of the company’s stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $0.60, for a total transaction of $21,271.80. Following the completion of the transaction, the chairman now owns 576,235 shares in the company, valued at $345,741. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Zynerba Pharmaceuticals Trading Down 4.8 %
Shares of ZYNE stock traded down $0.03 on Wednesday, hitting $0.60. The company’s stock had a trading volume of 128,532 shares, compared to its average volume of 264,483. The stock’s 50 day moving average is $0.57 and its 200-day moving average is $0.84. Zynerba Pharmaceuticals, Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.94.
Zynerba Pharmaceuticals (NASDAQ:ZYNE – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. As a group, sell-side analysts anticipate that Zynerba Pharmaceuticals, Inc. will post -0.86 earnings per share for the current year.
Analyst Upgrades and Downgrades
Institutional Investors Weigh In On Zynerba Pharmaceuticals
A number of large investors have recently bought and sold shares of ZYNE. Cetera Advisor Networks LLC acquired a new stake in Zynerba Pharmaceuticals during the second quarter worth about $28,000. Verition Fund Management LLC acquired a new stake in Zynerba Pharmaceuticals during the second quarter worth about $35,000. Jane Street Group LLC acquired a new stake in Zynerba Pharmaceuticals during the third quarter worth about $46,000. UBS Group AG grew its stake in Zynerba Pharmaceuticals by 145.2% during the first quarter. UBS Group AG now owns 27,621 shares of the company’s stock worth $56,000 after buying an additional 16,357 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Zynerba Pharmaceuticals during the third quarter worth about $90,000. 23.82% of the stock is currently owned by institutional investors and hedge funds.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery.
- Get a free copy of the StockNews.com research report on Zynerba Pharmaceuticals (ZYNE)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.